Transforming growth factor beta (TGFb) regulates cell adhesion, proliferation, and differentiation in a variety of cells. Smad proteins are receptor-activated transcription factors that translocate to the nucleus in response to TGFb. We demonstrate here that TGFb increases cell adhesion in metastatic PC3-M prostate cancer cells. TGFb treatment of PC3-M cells leads to nuclear translocation of R-Smad proteins. We show that Smad proteins are necessary, but not sufficient, for TGFbmediated cell adhesion. After showing that TGFb upregulated p38 MAP kinase activity in PC3-M cells, we show that inhibition of p38 MAP kinase partially blocked TGFb-mediated increase in cell adhesion, as well as nuclear translocation of Smad3. Finally, we show that Smad3 is phosphorylated by p38 MAP kinase in vitro. These findings implicate crosstalk between the MAP kinase and Smad signaling pathways in TGFb's regulation of cell adhesion in human prostate cells. This represents a mechanism by which the pleiotropic effects of TGFb may be channeled to modulate cell adhesion.
Introduction
Changes in cell adhesion and mobility contribute to the metastatic phenotype in human prostate cancer (Paul et al., 1997; Liu et al., 2000 Liu et al., , 2001 Liu et al., , 2002 Ozen and Pathak, 2000) . The manner by which prostate cells regulate these processes, however, is not well understood. Transforming growth factor b (TGFb) is a 25 kDa disulfide-linked homodimeric extracellular cytokine (Derynck and Feng, 1997) , which in addition to modulating proliferation and differentiation, has been implicated in the regulation of cell adhesion and motility in a variety of cell types, including hepatocellular carcinoma cells (Bissell et al., 2001) , glial cells (Xiao et al., 1996) , melanoma cells (Mooradian et al., 1990) , and breast cancer cells (Arteaga et al., 1990; Welch et al., 1990; Yin et al., 1999) . In human prostate, TGFb has been shown to increase cell adhesion, motility, and invasion of PC3 cells (Kostenuik et al., 1997; Festuccia et al., 1999) . Mechanistic studies have linked TGFb to a host of target genes related to the extracellular matrix, including fibronectin, collagen, integrins, and plasminogen activator inhibitor-1 (PAI-1) (Ignotz and Massague, 1986; Ignotz and Massague, 1987; Laiho and Keski-Oja, 1992; Kostenuik et al., 1997; Festuccia et al., 1999) .
TGFb signaling is complex, and has recently been reviewed (Massague, 2000; Attisano and Wrana, 2002; Dennler et al., 2002; Wakefield and Roberts, 2002) . Typically, TGFb binds to cell surface receptors, which in turn phosphorylate and activate Smad2 and/or Smad3. Smads then translocate to the nucleus, and regulate gene transcription (for reviews, see Miyazono et al., 2000; Moustakas et al., 2001) . There is limited information regarding Smads in prostate. Expression of Smads 2, 3, 4 and 7 has been reported in rat ventral prostate as well as rat prostate-derived Dunning TSU cells (Brodin et al., 1999; Latil et al., 1999) . Brodin et al. (1999) have shown that after castration of rats (a TGFbinducing maneuver), there is increased phosphorylation of Smad2, increased expression of Smads 3 and 4, and increased expression of Smads 6 and 7. Induction of Smad7 is responsible for TGFb-mediated apoptosis in human prostatic carcinoma cells, as loss of Smad7 function via antisense blocks the apoptotic response to TGFb in these cells (Landstrom et al., 2000) .
Despite knowledge that TGFb can modulate interactions with the extracellular matrix, little is known of the role of proximal signaling elements in potentially regulating these processes, particularly in prostate. Smad3 is essential for induction of PAI-1 by TGFb in mouse embryo fibroblasts, whereas both Smad2 and Smad3 are required for the growth arrest function of TGFb in these cells (Datto et al., 1999; Piek et al., 2001) . It is important to understand and characterize the proximal signaling elements involved in specific TGFbdependent effects. This is because TGFb signaling appears to employ common elements, involving Smads, yet exerts pleiotropic effects, which appear to be celltype specific, for review see Massague and Wotton (2000) . Recent reports suggest that the pleiotropic effects of TGFb result from 'crosstalk' by other signaling pathways such as the mitogen-activated protein kinase (MAPK) pathway, which then differentially modulates TGFb-dependent action (Zhang et al., 1998; Sano et al., 1999; Massague, 2000) . MAPKs have been shown to play a central role in mediating a diverse array of cellular signals, such as growth factor, cytokine and stress responses including growth arrest, apoptosis and recently, cell adhesion (for review see Kyriakis and Avruch, 2001) .
Many studies describe links between various MAPK members and TGFb signaling pathways. In some studies, TGFb has been shown to modulate the expression and/or activity of specific MAPK members (Hu et al., 1999; Olsson et al., 2001) . In other studies, MAPK members modulate TGFb activity, for example, p42/44 MAP kinase was shown to be important for TGFb-mediated furin gene transcription in hepatocytes (Blanchette et al., 2001) . However, there is essentially no information relating to crosstalk modulation of Smad activity in prostate cells or during cell adhesion. Prior studies do raise the notion that p38 MAP kinase could be important, however. p38 MAP kinase is upregulated by TGFb, and has been shown to modulate TGFbdependent extracellular matrix degradation in osteoblasts (Karsdal et al., 2001) . p38 MAP kinase has also been linked to TGFb function in fibroblasts (Ravanti et al., 1999) , hematopoietic progenitors (Verma et al., 2001) , T cells (Wagers and Kansas, 2000) , mouse myoblasts (Hanafusa et al., 1999) , and aortic smooth muscle cells (Yamamoto et al., 2001) . However, the mechanism by which p38 MAP kinase and TGFb pathways interact has not been identified. Exceptions can be found in two reports that show that TGFb activates p38 MAP kinase, leading to phosphorylation of activating transcription factor-2 (ATF-2), which in turn forms a complex with Smad4 (Hanafusa et al., 1999; Sano et al., 1999) . In this case, p38 MAP kinase and the Smads transduce distinct, parallel signals to the nucleus, where their activities converge.
Identification and characterization of proximal TGFb signaling pathways involved in TGFb-mediated cell adhesion in human prostate are therefore likely to provide important information with respect to understanding how cells regulate this critical and basic process. To do so, we first focused upon the role of Smad signaling in PC3-M prostate cancer cells. PC3-M cells are a widely used established metastatic variant cell line, previously characterized by us (Bergan et al., 1996b; Kyle et al., 1997) , as well as others (Kozlowski et al., 1984) . As such, they provide a useful model for understanding the precise pathways by which TGFb regulates adhesion in metastatic prostate cancer. After demonstrating that Smads were necessary for TGFb-mediated cell adhesion, we went on to characterize how TGFb signals were modulated by p38 MAP kinase, through modulation of Smad pathway activation. Taken together, this study provides new information on the biochemical regulation of prostate cell adhesion by TGFb; thus, linking a critical biological process with a cytokine implicated in cellular regulation and dysregulation.
Results

TGFb increases adhesion in PC3-M cells
To examine the role of TGFb in mediating prostate cell adhesion, we treated PC3-M cells with different concentrations of TGFb for 24 h, and measured effects upon cell adhesion. As shown in Figure 1 , TGFb increased cell adhesion by 86%, compared to control cells. There was a dose-response relation between TGFb and magnitude of cell adhesion for concentrations of TGFb between 0.0625 and 2.0 ng/ml. Above 2 ng/ml, no further increase in cell adhesion was observed. TGFb had no effect upon cell adhesion when added to adhering cells, that is, during the 2 h duration of the adhesion assay, or when added as a pretreatment for 6 h or less (data not shown). While at least five subtypes of TGFb (TGFb1-5) have been identified to date, only TGFb1, b2, and b3 exert physiologic effects upon human epithelial cells (Lucia et al., 1998) . Although likely exerting differing physiologic effects in vivo, in vitro the activities of TGFb1, b2, and b3 tend to be identical (Roberts, 1998) . We have previously shown this to be the case for TGFb's effects upon PC3-M cells (Rohlff et al., 1998) . Thus, current investigations focused upon TGFb1.
Adhesion assays were performed in the presence of serum, and serum is known to contain varied levels of all three subtypes of TGFb. In addition, we have recently shown that PC3-M cells secrete TGFb1, but not TGFb2 (Liu et al., 2001) . It was therefore possible that serumderived, as well as cell-secreted TGFb, was exerting effects upon cell adhesion in the current system. To TGFb-mediated cell adhesion is dependent upon activation of Smads
To investigate the role of Smads in TGFb-mediated cell adhesion, we first assessed whether TGFb could activate R-Smads, as measured by nuclear translocation. In these studies, nuclear and cytosolic cell fractions were isolated, and probed for Smads by an antibody that recognizes Smad3, Smad2 and Smad1. The quality of individual preparations was evaluated by probing for DNAdependent protein kinase and a-tubulin, proteins associated with the nucleus and the cytoplasm, respectively. As can be seen (Figure 2a ), a-tubulin was present only in the cytosolic fraction, while DNA-dependent protein kinase was greatly enriched in the nuclear fraction. In untreated cells, the majority of Smad2 and Smad3 protein is predominantly present in the cytoplasm. Smad1 was not detected. Treatment of PC3-M cells with TGFb caused nuclear accumulation of both Smad2 and Smad3, and a corresponding decrease in cytosolic levels of Smad2 and Smad3. Identification of individual Smad proteins was confirmed by reprobing the blot with phospho-Smad2-specific antibody (data not shown).
In order to better understand the kinetics of Smad activation in these cells, cells were treated with TGFb for 0-360 min ( Figure 2b ). As a measure of Smad activation, nuclear fractions were assayed for Smad proteins. TGFb led to a transient accumulation of Smad2 and Smad3 in the nucleus, with maximal nuclear levels of Smads occurring within 60-180 min of treatment. Nuclear accumulation of the Smads returned to baseline levels by 360 min after treatment with TGFb.
Next, we sought to determine the importance of Smads in TGFb-mediated cell adhesion. In order to measure only the adhesion of transfected cells, a constitutive luciferase expression vector was cotransfected as a marker of transfection. Cells were also transfected with one of the following: wild-type Smad3, a dominant-negative, activation-defective Smad3 expression vector (Smad3A), or an empty vector control. Cells were then treated with TGFb (or not), and their ability to adhere was measured. By comparing the ratio of luciferase activity in washed versus unwashed cells, changes in cell adhesion of only the transfected cells could be followed. In cells transfected with control vector, TGFb increased cell adhesion by 86% ( Figure 2c ). While wild-type Smad3 modestly enhanced TGFb's effects, dominant-negative Smad3A completely abrogated TGFb's effects. The results of this assay were confirmed by repeating the experiment, but this time measuring TGFb-mediated cell adhesion in all cells (transfected plus nontransfected) after transient transfection. Similar effects were observed (data not shown). It was not surprising that we could see the effect of Smad expression in the transfected cells, while measuring the adhesion of all cells in the population, given that transfection rates were above 70%, as measured by FACS analysis (data not shown).
p38 MAP kinase modulates TGFb-induced cell adhesion
Above findings demonstrated that R-Smads are necessary for TGFb's effects upon cell adhesion. Given the common use of R-Smads in TGFb signaling, and the fact that TGFb exerts many different biological effects, we looked for factors that could comodulate Smad Figure 2 TGFb-dependent cell adhesion is mediated through the Smad pathway. (a) PC3-M cells were treated for 30 min with 2 ng/ ml TGFb1 (or buffer for controls). Subcellular fractionation was performed as outlined in Materials and methods. Equal amounts of protein from nuclear and cytosolic fractions were then probed for Smad1/2/3, DNA-PK or a-tubulin proteins by Western blot, as described in Materials and methods. (b) PC3-M cells were treated with 1 ng/ml TGFb1 or buffer for 0, 10, 60, 180, or 360 min. Cells were harvested and fractionated as above. Equal amounts of nuclear proteins were subjected to Western analysis using Smad1/2/ 3 antibody, (c) PC3-M cells were transiently transfected with CMVluciferase plasmid, along with either pEXL (empty vector), pEXLSmad3 (Smad3), or pEXL-Smad3A (dominant-negative Smad3A). After 24 h, cells were treated with 1 ng/ml TGFb1 (or buffer for controls) overnight, and cell adhesion measured by the luciferase reporter method, as described in Materials and methods. Depicted is the mean7s.e.m. (n ¼ 4) increase in cell adhesion by TGFb1 p38 MAP kinase and Smad in prostate cell adhesion SA Hayes et al activity. As prior investigations implicate MAP kinase family members, studies focused upon this family of proteins. We first examined the ability of a panel of MAP kinase pathway inhibitors to block TGFbmediated cell adhesion. In this experiment, PC3-M cells were preincubated with previously characterized chemical inhibitors of MEK1/2, raf or p38 MAP kinase, for 2 h prior to treatment with TGFb, and effects upon cell adhesion measured (Figure 3a) . While TGFb-mediated increases in cell adhesion were preserved in the face of treatment with inhibitors of either MEK1/2 (U0126 and PD98059) or c-raf (ZM336372), TGFb-mediated increases in cell adhesion were limited to only 16% in cells pretreated with the p38 MAP kinase inhibitor, SB203580.
To examine the effect of SB203580 further, cells were treated with various concentrations of TGFb for 24 h in the presence or absence of SB203580, and effects upon cell adhesion were measured (Figure 3b ). SB203580 decreased cell adhesion in the presence of TGFb, although effects became minimal as TGFb concentration approached 1.0 ng/ml. If the effect of SB203580 upon cell adhesion was in fact TGFb dependent, then SB203580 should have minimal effect in the absence of TGFb. This was shown to be the case by demonstrating that SB203580 had no effect upon cell adhesion in cells treated with TGFb blocking antibody. SB203580 treatment did not decrease cell viability (data not shown). Taken together, these studies suggest that p38 MAP kinase activity is necessary, at least in part, for TGFb's effects upon prostate cell adhesion.
If p38 MAP kinase were in fact important for TGFb action, then disruption of p38 MAP kinase signaling by expression of a kinase-deficient, dominant-negative p38 MAP kinase should also diminish the effects of TGFb. This hypothesis was tested by transiently transfecting cells with the p38AGF dominant-negative construct, as well as the wild-type p38 MAP kinase, and measuring the effect of TGFb upon cell adhesion. As can be seen in Figure 3c , expression of p38 MAP kinase led to increased adhesion, while p38AGF inhibited TGFbmediated increases in cell adhesion by 37%, an effect closely matching that attained when p38 MAP kinase was inhibited by SB203580.
As TGFb has been shown to induce p38 MAP kinase activity in other cell types, we investigated this possibility in human prostate cells. In this experiment, PC3-M cells were treated with TGFb for up to 24 h, and Figure 3 p38 MAP kinase modulates TGFb's effect upon cell adhesion. In (a), cells were pretreated for 2 h with 10 mm of the following inhibitors: SB203580 (p38 MAP kinase inhibitor), PD98059 (MEK inhibitor), ZM336372 (c-raf inhibitor), U0126 (MEK1/2 inhibitor), SB202474 (negative control drug), or solvent alone (0.05% DMSO). Cells were then treated with 0.5 ng/ml TGFb1 (or buffer) overnight. In (b), cells were pretreated 2 h with 10 mm SB203580 (or DMSO for controls), and then with 0-1.0 ng/ml TGFb1, as indicated, or with 2.5 mg/ml TGFb antibody overnight. Cell adhesion was then measured, and results depicted as the mean 7s.e.m. (n ¼ 4) percentage of adherent cells, relative to controls, In (c), PC3-M cells were transiently transfected with either pCMV5 (empty vector), pCDN-p38 (wild-type p38 MAP kinase), or pCMV5-p38AGF (dominant-negative p38 MAP kinase). After 24 h, cells were replated and treated overnight with 1 ng/ml TGFb1 (or buffer as a control). Cell adhesion was then measured using the luciferase reporter method, as described in Materials and methods. The mean 7s.e.m. (n ¼ 4) percent of adherent cells, relative to untreated control cells, is depicted " p38 MAP kinase and Smad in prostate cell adhesion SA Hayes et al then levels of phospho-p38 MAP kinase protein (i.e., activated p38 MAP kinase), as well as total p38 MAP kinase protein were measured by Western blot. TGFb increased p38 MAP kinase phosphorylation within 30 min, maintaining high levels for at least 18 h (Figure 4 ). Despite modest TGFb-induced increases in p38 MAP kinase protein levels, relatively high levels of p38 MAP kinase phosphorylation were maintained for all post-TGFb treatment time points examined. Conversely, treatment with TGFb antibody led to a decrease in p38 MAP kinase phosphorylation.
p38 MAP kinase regulates Smad activation
The above studies demonstrate that R-Smad-dependent signaling is necessary for TGFb to increase prostate cell adhesion, and that p38 MAP kinase modulates TGFb's effect. To investigate the possibility that p38 MAP kinase-mediated modulation of TGFb signaling was being mediated at the level of Smad protein, we first evaluated whether p38 MAP kinase was important in modulating the activation of Smads by TGFb. In this experiment, p38 MAP kinase was inhibited by pretreating cells with SB203580, and the effect on TGFbinduced nuclear translocation of Smads was measured (Figure 5a ). Treatment with SB203580 significantly decreased, but did not totally abrogate, nuclear accumulation of Smad3, while minor effects upon Smad2 were observed. Western blots were reprobed for the basal transcription factor TATA binding protein (TBP), similar in molecular weight to Smad proteins, to confirm equal loading of nuclear proteins. This finding demonstrated that p38 MAP kinase was important in regulating Smad3 activation, and raised the notion that p38 MAP kinase may be directly interacting with Smad3. p38 MAP kinase is a serine/ threonine kinase known to regulate phosphorylation (i.e., activation) of a number of transcription factors, such as SAP-1 (Galanis et al., 2001 ) and STAT1 (Kovarik et al., 1999) , possibly through direct binding and phosphorylation. As both Smad2 and Smad3 have a number of known phosphorylation sites (for review see Moustakas et al., 2001) , we investigated whether p38 MAP kinase could be a regulating Smad activity through direct modulation. First, cells were subjected to osmotic shock (a standard maneuver for activating p38 MAP kinase), or not for control cells, and then p38 MAP kinase was immunoprecipitated. Next, recombinant Smad2-or Smad3-GST fusion proteins, or GST control protein, were added to an in vitro kinase reaction in the presence of radioactive ATP. The level of protein phosphorylation was then evaluated by separating proteins by gel electrophoresis, and visualizing by autoradiography. As seen in Figure 5b , Smad3 was Figure 4 TGFb activates p38 MAP kinase. PC3-M cells were treated with 2.5 mg/ml anti-TGFb neutralizing antibody for 18 h, or with 2 ng/ml TGFb1 for either 0.5, 2, or 18 h. p38 MAP kinase activation status was then determined by probing for phospho-p38 MAP kinase, as well as total p38 MAP kinase, by Western blot. The ratios of the band intensities of phospho-p38 MAP kinase to total p38 MAP kinase are depicted in the graph Figure 5 p38 MAP kinase regulates Smad3 activation, In (a), PC3-M cells were pretreated for 30 min with SB203580 (or DMSO for controls) followed by 30 min treatment with 0.5 ng/ml TGFb1 (or buffer for controls), as indicated. Nuclear extracts were probed for total Smad protein by Western blot. Equal gel loading was confirmed by probing for TBP. In (b), p38 MAP kinase was first activated by osmotic shock (incubating PC3-M cells in 300 mm NaCl for 30 min), and then phospho-p38 MAP kinase was immunoprecipitated from equal amounts of cell protein. GSTSmad2, GST-Smad3, or GST only control proteins were then added to individual in vitro kinase reactions, as indicated, in the presence of g-[32]P-ATP p38 MAP kinase and Smad in prostate cell adhesion SA Hayes et al phosphorylated by p38 MAP kinase, while Smad2 and GST were not phosphorylated. As expected, Smad3 phosphorylation was enhanced during osmotic shock. These data demonstrate that p38 MAP kinase, or closely associated proteins, can phosphorylate Smad3. Lack of phosphorylation of Smad2 and GST demonstrates that phosphorylation is specific. Increased phosphorylation after osmotic shock provides further evidence that Samd phosphorylation is dependent upon p38 MAP kinase activity.
Discussion
TGFb was shown to increase adhesion in metastatic human prostate cells. This effect by TGFb was consistent with that previously reported in other cell types (6-13). Under serum-containing tissue culture conditions, a dose-response relation between TGFb and cell adhesion was observed after the addition of TGFb, as well as after the subtraction of TGFb (i.e., in the presence of TGFb blocking antibody). As TGFb concentration is not constant in different lots of serum, investigators must take this into consideration when designing experiments where the degree of TGFb effect upon cell adhesion may affect results. Given that TGFbdependent effects upon cell adhesion required long exposure times (i.e., longer than 6 h), it is likely that changes in gene expression are necessary. This is supported by prior studies demonstrating that TGFb modulates expression of genes in various cell types associated with adhesion and motility, including: integrins, collagen, and PAI-1 (Ignotz and Massague, 1986; 1987; Laiho and Keski-Oja, 1992; Kostenuik et al., 1997; Festuccia et al., 1999) . It is also supported by the current study, where TGFb action upon cell adhesion required activation of Smads, which are known transcription factors. It will be important to determine which TGFb-dependent gene products are mediating changes in prostate cell adhesion.
While TGFb has long been linked to adhesion, this is the first report describing the regulation of the proximal signaling events involved in linking TGFb with this important cellular function. After demonstrating that TGFb did in fact lead to Smad activation, as measured by both phosphorylation and nuclear translocation, the requirement for Smads in TGFb-mediated cell adhesion was demonstrated.
As both Smad2 and Smad3 translocated to the nucleus after TGFb treatment, it was important to block the function of both of these R-Smads. The dominant-negative Smad3 that we used was designed to occupy the TGFb receptor Smad binding site without becoming phosphorylated, and thus acts to prevent activation of all receptor-associated Smads (R-Smads), that is, Smad2 and Smad3 (Nakao et al., 1997) . Although both Smads are activated in response to TGFb treatment, we cannot, at this time, exclude the possibility that only one of the R-Smads is necessary for TGFbmediated effects upon cell adhesion. It should be noted that there are instances where Smad2 and Smad3 exert different mechanistic effects, in other cell systems .
By cotransfecting a constitutive luciferase reporter gene, we were able to follow specifically the adhesion of only the transfected cells after transient transfection. To our knowledge, this is a novel and potentially powerful assay, which can be generally applied to investigate the role of other genes, as they may relate to modulation of cell adhesion.
Our search for modulators of Smad activity was driven by the idea that TGFb exerts pleiotropic effects, yet transduces signals through a common Smad pathway, whose activity appears to be commonly regulated by other signaling pathways (Massague and Wotton, 2000) . Prior reports implicate p38 MAP kinase in mediating cell adhesion-associated pathways (Paine et al., 2000) . In addition, prior reports also show that p38 MAP kinase is activated by TGFb (Hanafusa et al., 1999; Yamamoto et al., 2001; Bakin et al., 2002; Wang et al., 2002; Yu et al., 2002; Ungefroren et al., 2003) . We hypothesized that p38 MAP kinase was modulating Smad activation. We have demonstrated that increased cell adhesion by TGFb is dependent, at least in part, upon p38 MAP kinase activity. The p38 MAP kinase inhibitor SB203580, which functions by binding to the ATP binding region of p38 MAP kinase, is a specific inhibitor of p38a and p38b; other isoforms of p38 MAP kinase, as well as other MAP kinase family members, are not inhibited by SB203580 (Tong et al., 1997; Wilson et al., 1997) . Evidence for the role of p38 MAP kinase in this process was strengthened by dominant-negative as well as overexpression data. Importantly, while p38 MAP kinase clearly modulated Smad activation, it did not totally abrogate it. This is consistent with other investigations that show that both p38 MAP kinase and Smad are activated by TGFb, with Smad being directly phosphorylated by the TGFb receptor Ungefroren et al., 2003) .
Importantly, we demonstrated that the mechanism by which p38 MAP kinase regulates TGFb signaling appears to be at the level of Smad activation. Smad3 nuclear translocation was blocked by inhibition of p38 MAP kinase, implicating Smads as targets for modulation by p38 MAP kinase. This notion was further supported by demonstrating that p38 MAP kinase, or closely associated proteins, phosphorylated Smad3 in vitro. It is not clear at this time whether the lack of Smad2 phosphorylation by p38 MAP kinase in vitro is due to real differences in substrate specificity, or whether it is an artefact of in vitro analysis. It is possible that cofactor proteins may be necessary to facilitate Smad phosphorylation by p38 MAP kinase, and that the ones required for Smad2 were not present in the in vitro assay system. Ungefroren et al. (2003) report that inhibition of p38 MAP kinase did not alter Smad2 phosphorylation, consistent with our in vitro findings. However, Smad2 expression and activation in PC3-M cells was low overall, particularly in comparison to Smad3, precluding definitive conclusions about p38 MAP kinase modulation of Smad2.
p38 MAP kinase and Smad in prostate cell adhesion SA Hayes et al
The effect of SB203580 upon TGFb-mediated cell adhesion was diminished when higher concentrations of TGFb were used, demonstrating that inhibition of p38 MAP kinase could be overcome in the presence of excess TGFb. This finding is consistent with the notion that while p38 MAP kinase can modulate TGFb signaling, it is not necessary for it. We chose not to examine the effects of higher concentrations of SB203580 in the current system out of concern that with high concentrations of a chemical inhibitor, particularly of kinases, there would be loss of specificity. Instead, we sought to corroborate these findings by using dominant-negative p38 MAP kinase. Interestingly, both SB203580 and dominant-negative p38 MAP kinase studies gave similar results, both inhibiting TGFb's effect upon cell adhesion by roughly half. This study demonstrates that p38 MAP kinase modulation of Smad activity provides a new level of regulation by which cells can modulate the TGFb signal, and that in PC3-M cells, it is associated with modulation of cell adhesion. Finally, it was important that we demonstrated that Smad3 could be phosphorylated in vitro by p38 MAP kinase, or a closely associated protein.
p38 MAP kinase could be modulating Smad activation in one of several ways. Unactivated Smad proteins can be compartmentally sequestered by anchoring, for instance, to SARA or to microtubules (Dong et al., 2000) . p38 MAP kinase could govern the regulation of this anchoring process. Alternatively, Smads could be direct or indirect targets of p38 MAP kinase phosphorylation, at a site distinct from the TGFbR-mediated phosphorylation/activation, but one that promotes receptor activation of the Smads. Amino-acid sequences that promote direct phosphorylation by p38 MAP kinase have been detected (Fantz et al., 2001; Galanis et al., 2001) , but a complete understanding of substrate selection by the kinase remains elusive. Smad2 and Smad3 do possess S/TP motifs, which are phosphorylated by MAP kinases including p38 MAP kinase, but do not contain docking domains similar to the sequences important for p38 MAP kinase phosphorylation of SAP-1 (Galanis et al., 2001) .
TGFb was shown to induce p38 MAP kinase in PC3-M cells, which in turn was shown to regulate Smad activation. TGFb activation of various members of the MAPK signaling pathway, including p38 MAPK, has been observed in other cell systems (Schnaper, 1998; Hanafusa et al., 1999; Hayashida et al., 1999; Ravanti et al., 1999; Verma et al., 2001; Yamamoto et al., 2001 ). In addition, it has previously been reported that TGFb activates p42/p44 MAP kinase during furin gene transcription, and that activation is important for Smad nuclear translocation (Blanchette et al., 2001) . However, to our knowledge, this is the first report demonstrating that TGFb-mediated activation of p38 MAP kinase is important for Smad activation.
Since overexpression and dominant-negative p38 MAP kinase expression both modulate the effect of TGFb on adhesion in PC3-M cells, p38 MAP kinase activity appears to be present in limiting quantity in the current system. Loss of p38 MAP kinase activity, therefore, may represent a mechanism by which cells lose responsiveness to TGFb. We focused investigations upon human prostate because TGFb plays key regulatory roles in this cell type, and because dysregulation of TGFb signaling has been linked to human prostate cancer 1996a, b; Sehgal et al., 1996) . We (Rohlff et al., 1998; Liu et al., 2002) and others (Hsing et al., 1996; Kostenuik et al., 1997; Wilding et al., 1989; Festuccia et al., 1999) have shown that TGFb is an important regulator of both cell growth, as well as adhesion and motility, in human prostate. Differential responsiveness to TGFb has been reported in metastatic versus primary prostate cells (Sehgal et al., 1996) , while loss of TGFb receptor accompanies progression of human prostate cancer (Kim et al., 1996a ). In the current study, we show that Smad proteins play a necessary role in modulating TGFb's effects upon prostate cell adhesion. In addition, we show that p38 MAP kinase can modulate Smad phosphorylation and activation, and thus identify this as a novel mechanism for regulation of Smad pathway activation, and regulation of cell adhesion.
Materials and methods
Materials
The origin of PC3-M cells was previously described (Kozlowski et al., 1984; Kyle et al., 1997) ; they were cultured in RPMI 1640 (Gibco, Grand Island, NY, USA) containing 10% heat-inactivated fetal bovine serum (Biofluids, Rockville, MD, USA), 10 mm HEPES-KOH (pH ¼ 7.6), l-glutamine and penicillin/streptomycin. TGFb1 (R&D Systems, Minneapolis, MN, USA) was resuspended and stored according to the manufacturer's recommendation. Constitutively active, CMVluc, luciferase reporter vector was from Stratagene (La Jolla, CA, USA). Smad3, dominant-negative Smad3, and control vector constructs, pEXL-Smad3, pEXL-Smad3A, and pEXL, respectively, were graciously provided by Harvey Lodish, Whitehead Institute, Cambridge, MA, USA, and have been previously described (Liu et al., 1997) . The p38 MAP kinase plasmid, pCDN-p38, was obtained from Dr Peter Young (SmithKline Beecham, King of Prussia, PA, USA) and has been previously described (Kumar et al., 1997) . The dominantnegative p38 expression plasmid pCMV5-p38AGF was obtained from Roger Davis (University of Massachusetts, Worcester, MA, USA) and has been previously described (Derijard et al., 1995) . Antibodies were obtained from the following sources: Pan-specific TGFb neutralizing antibody, clone 1D11 R&D Systems (Minneapolis, MN, USA); Smad1/ 2/3, clone H2, DNA-dependent protein kinase (DNA-PK), clone H163, and TATA binding protein, clone N12, Santa Cruz Biotechnology (Santa Cruz, CA, USA); a-tubulin, clone Ab-1, Oncogene Science (Cambridge, MA, USA); phosphoSmad2, Upstate Biotechnology (Lake Placid, NY, USA); p38 MAP kinase and phospho-p38 MAP kinase, clones 9212 and 9211, respectively, Cell Signaling Technology (Beverly, MA, USA). U0126 and PD98059 (inhibitors of MEK1/2), ZM336372 (c-raf inhibitor), SB203580 (p38 MAP kinase inhibitor), and SB202474 (kinase inhibitor control, i.e., a structurally related chemical that lacks inhibitory effects toward MAP kinase family members) were all obtained from CalBiochem (San Diego, CA, USA), and were stored as stocks in DMSO, and thawed just prior to use.
Cell adhesion assays
Cell adhesion was measured as previously described by us, with modifications (Kyle et al., 1997; Liu et al., 2001) . Briefly, 24 h after plating, cells were pretreated overnight with TGFb1 and/or other chemical agents, as indicated. Then, cells were removed by trypsin/EDTA, and 25 000 cells were plated into each well of a 48-well tissue culture plate (Corning International, Corning, NY, USA) and 2 h later, nonadherent cells were removed by washing three times with phosphate buffered saline (PBS). Adherent cells were fixed for 30 min with 2% formalin in PBS, air-dried, stained for 30 min with freshly prepared and filtered 0.1% crystal violet in PBS, washed three times with water, and cells were air-dried. Bound dye was solubilized with 10% acetic acid and absorbance measured at 595 nm. Cell-free wells were run with each experiment, and served as blanks. Equal cell loading was verified by staining a parallel set of cells, which were also plated into 48-well plates, but not washed. All experiments were run in replicates of four, and were repeated at least three times.
Adhesion of transfected cells was measured in the following way. Cells, plated the previous day into six-well plates, were transfected using Lipofectamine (Invitrogen, Carlsbad, CA, USA) with 500 ng pCMV-luc plasmid (Stratagene Flagluciferase control vector, La Jolla, CA, USA) and 500 ng expression plasmid, according to Lipofectamine manufacturer's protocol. The use of luciferase vector allowed the measurement of adhesion of transfected cells only. After a 24 h recovery period, cells were treated with TGFb1 overnight, or buffer only for controls. In quadruplicate, cells were then plated in two identical 48-well plates. After 2 h, one plate was washed with PBS, and the other was not washed. Adherent cells were then lysed and luciferase activity measured according to the manufacturer's protocol (Promega, Madison, WI, USA). The ratio of luciferase activity in washed to unwashed cells was then determined, thus providing a measure of cells remaining after washing.
Subcellular fractionation
After washing with PBS, cells were harvested by scraping, washed 1X in PBS, and lysed in five pellet volumes Buffer A (10 mm KCl, 10 mm HEPES-KOH, pH 7.6, 1.5 mm MgCl 2 1 mm DTT, 0.5 mm PMSF) for 10 min on ice, followed by mechanical disruption by passing through a 25 gauge needle 10 times. Lysis was verified by microscopy. Nuclei were spun down 5 min at 1600 g at 41C, and supernatant was retained as the cytosolic fraction. Nuclear proteins were extracted in 2.5 pellet volumes Buffer C (420 mm NaCl, 10 mm HEPES-KOH pH ¼ 7.6, 1.5 mm MgCl 2 , 1 mm DTT, 0.5 mm PMSF) for 15 min on ice.
Western blotting
Western blots were performed as previously described (Bergan et al., 1996a) , with modifications. Briefly, equal amounts of protein were separated on a 10% sodium dodecyl sulfate polyacrlyamide gel (SDS-PAGE) under reducing conditions, and transferred onto nitrocellulose (Schleicher and Schuell, Keene, NH, USA), in a wet transfer cell (Bio-Rad, Hercules, CA, USA). Blots were blocked with 5% nonfat milk in TBST (10 mm Tris-HCl (pH ¼ 7.6), 80 mm NaCl, 0.08% Tween-20). Smad1/2/3 antibody (clone H-2, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was diluted 1 : 500; DNA-PK antibody (clone H-163, Santa Cruz Biotechnology) was diluted 1 : 100; cmyc antibody (clone N-262, Santa Cruz Biotechnology) was diluted 1 : 500; a-tubulin antibody (clone Ab-1, Oncogene Sciences, Cambridge, MA, USA) was diluted 1 : 1000; phospho-p38 antibody (clone 9211, Cell Signaling Technology, Beverly, MA, USA) was diluted 1 : 100; p38 antibody (clone 9212, Cell Signaling Technology) was diluted 1 : 100; phosphoSmad2 (Upstate Biotechnology, Waltham, MA, USA) was diluted 1 : 250; TBP antibody (clone N-12, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was diluted 1 : 100. Proteins were then detected with an anti-mouse-HRP-conjugated secondary antibody (Bio-Rad, Hercules, CA, USA) diluted 1 : 1500, or anti-rabbit-HRP-conjugated secondary antibody (Amersham, Piscataway, NJ, USA) and visualized with the ECL detection system (Amersham, Piscataway, NJ, USA) according to the manufacturer. The intensity of individual bands was quantitated by generating an electronic image with a scanner, and quantitating band intensity using ImageJ software (NIH, Bethesda, MD, USA).
In vitro kinase reactions
Cell lysis, immunoprecipitation, and kinase assay reactions were all carried out utilizing reagents contained within the manufacturer's p38 MAP Kinase Assay Kit (Cell Signaling Technology, Inc., Beverly, MA, USA), according to manufacturer's instructions, with modifications. Exponentially growing, nonconfluent, cells were lysed (in 20 mm Tris (pH 7.5), 150 mm NaCl, 1 mm EDTA, 1 mm EGTA, 1% Triton, 2.5 mm sodium pyrophosphate, 1 mm b-glycerolphosphate, 1 mm Na 3 VO 4 , 1 mg/ml leupeptin, 1 mm PMSF, and Phosphatase Inhibitor cocktail I and cocktail II (both from Sigma, both at 1 : 100 dilution). After clarification, phospho-p38 MAP kinase was immunoprecipitated from 200 mg of protein, over night at 41C, using phospho-p38 MAP kinase polyclonal antibody (Thr180/Tyr182) crosslinked to agarose beads. Immunoprecipitates were washed 2X with lysis buffer, 1X with kinase buffer (25 mm Tris (pH 7.5), 5 mm b-glycerolphosphate, 2 mm DTT, 0.1 mm Na 3 VO 4 , 10 mm MgCl 2 ), and then suspended in 50 ml kinase buffer. The following proteins were added to separate kinase reactions, as indicated: 300 ng of either recombinant GST-Smad2 or GST-Smad3, or 2 mg GST (all from Cascade BioSciences, Inc., Winchester, MA, USA). After addition of 5 mCi gamma-[32]P-ATP (3000 Ci/mmol; Amersham), the reaction mixture was incubated at 301C Â 30 min, and quenched by boiling in Laemmli loading buffer X5 min. Reaction products were then separated by SDS-PAGE under reducing conditions, and visualized by autoradiography.
